A phase 1b/2 study of cabozantinib in combination with pembrolizumab in advanced cutaneous melanoma.

Zakharia Y, Kim D, Freesmeier M, Frees M, Mott S, Monga V, Laux D, Javed A, Rieth J, Smestad J, Milhem M

Open source

DOI
10.1002/cncr.70326
Published
2026 Feb 15
Container
Cancer
Publisher
Not recorded
Open access
yes

Credibility signals

limited evidence Score 45/100 under policy 1.0.0. This is a metadata assessment, not a judgment of the paper's conclusions.

Show all credibility signals

Cite this work

BibTeX

@article{allodium:10.1002/cncr.70326,
  title = {A phase 1b/2 study of cabozantinib in combination with pembrolizumab in advanced cutaneous melanoma.},
  author = {Zakharia Y and Kim D and Freesmeier M and Frees M and Mott S and Monga V and Laux D and Javed A and Rieth J and Smestad J and Milhem M},
  year = {2026},
  journal = {Cancer},
  doi = {10.1002/cncr.70326},
  url = {https://doi.org/10.1002/cncr.70326}
}

RIS

TY  - JOUR
TI  - A phase 1b/2 study of cabozantinib in combination with pembrolizumab in advanced cutaneous melanoma.
AU  - Zakharia Y
AU  - Kim D
AU  - Freesmeier M
AU  - Frees M
AU  - Mott S
AU  - Monga V
AU  - Laux D
AU  - Javed A
AU  - Rieth J
AU  - Smestad J
AU  - Milhem M
PY  - 2026
JO  - Cancer
DO  - 10.1002/cncr.70326
UR  - https://doi.org/10.1002/cncr.70326
ER  - 

APA

Y, Z., D, K., M, F., M, F., S, M., V, M., D, L., A, J., J, R., J, S., & M, M. (2026). A phase 1b/2 study of cabozantinib in combination with pembrolizumab in advanced cutaneous melanoma.. Cancer. https://doi.org/10.1002/cncr.70326

Source records